Elagolix Sodium

Therapeutic Segment Endometriosis

CAS No. 832720-36-2

Regulatory Filing USDMF

Development Status DMF Filed

Molecule Type Small Molecule

Enquire Now

Mechanism of Action

Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland resulting in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

Disclaimer: No information in this Catalog – including any reference to any product or service – constitutes an offer for sale or be constructed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, under Bolar Provision the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of patent scenario for their respective markets and will be responsible for all patent related liabilities.